{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:23:03Z","timestamp":1784989383287,"version":"3.55.0"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Metamizole (MT), also known as dipyrone, is an analgesic and antipyretic drug labeled for use in humans and domestic animals in some countries. As with other drugs, the administration of MT in donkeys is based on studies carried out with horses. In the present report, we aimed to determine the pharmacokinetics of the two main metamizole active metabolites (N\u2010methyl\u20104\u2010aminoantipyrine [MAA] and 4\u2010aminoantipyrine [AA]) following 10 (M<jats:sub>10<\/jats:sub>) and 25\u00a0mg\/kg (M<jats:sub>25<\/jats:sub>) IV metamizole doses in Northeast Brazilian donkeys (<jats:italic>n<\/jats:italic>\u00a0=\u00a010). Blood was collected at predetermined times within over 48\u00a0h; MAA and AA plasma concentrations were determined by a validated LC\u2010MS\/MS method. The metabolites were quantifiable in the M<jats:sub>10<\/jats:sub> until 12\u00a0h and M<jats:sub>25<\/jats:sub> until 24\u00a0h after drug administration. As expected, AUC<jats:sub>0\u2192t<\/jats:sub>, AUC<jats:sub>0\u2192\u221e,<\/jats:sub> and C<jats:sub>max<\/jats:sub> demonstrated significant differences increases in metamizole metabolites profiles when groups were compared. No adverse effects were observed. This study indicates the need for an extremely sensitive analytical method to adequately characterize the pharmacokinetics of active metabolites of MT, MAA, and AA. In conclusion, the method developed in this research was able to measure the active metabolites of metamizole and with that it was possible to establish their pharmacokinetic profile. Furthermore, after projection of the minimum MAA concentrations, it is possible to infer that the dose of 10\u00a0mg\/kg will be used on donkeys at 6\u00a0h intervals, while the M25 group at 12\u00a0h intervals. However, clinical studies are needed to assess this hypothesis.<\/jats:p>","DOI":"10.1111\/jvp.12998","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T05:32:50Z","timestamp":1626413570000},"page":"842-849","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetic properties of metamizole active metabolites in Northeastern Brazilian donkeys (<i>Equus asinus<\/i>)"],"prefix":"10.1111","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8274-8797","authenticated-orcid":false,"given":"Lu\u00e3 B.","family":"de Mac\u00eado","sequence":"first","affiliation":[{"name":"Universidade Federal Rural do Semi \u00c1rido Mossor\u00f3 RN Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0319-2696","authenticated-orcid":false,"given":"Andressa N.","family":"Mouta","sequence":"additional","affiliation":[{"name":"Universidade Federal Rural do Semi \u00c1rido Mossor\u00f3 RN Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9073-1995","authenticated-orcid":false,"given":"Gabriel","family":"Ara\u00fajo\u2010Silva","sequence":"additional","affiliation":[{"name":"Universidade do Estado do Amap\u00e1 Macap\u00e1 AP Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0642-0033","authenticated-orcid":false,"given":"Jose Trinidad P.","family":"Urizar","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de San Luis Potos\u00ed San Luis Potos\u00ed \u2010 SLP Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4292-4861","authenticated-orcid":false,"given":"Val\u00e9ria V.","family":"de Paula","sequence":"additional","affiliation":[{"name":"Universidade Federal Rural do Semi \u00c1rido Mossor\u00f3 RN Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.44.101802.121347"},{"key":"e_1_2_9_3_1","unstructured":"ANVISA BRASILAg\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Resolu\u00e7\u00e3o da Diretoria Colegiada\u2010RDC N\u00ba 166.2017. Available at:http:\/\/portal.anvisa.gov.br\/"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jevs.2016.08.005"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/147323001003800419"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jevs.2015.03.005"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917\u2010016\u20100891\u20105"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2019.00022"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197984"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2012.07.029"},{"key":"#cr-split#-e_1_2_9_11_1.1","unstructured":"EMEA (European Agency for the Evaluation of Medicinal Products)(2003).Committee for Veterinary Medicinal Products - Metamizole - Summary Report"},{"key":"#cr-split#-e_1_2_9_11_1.2","unstructured":"(2) EMEA\/MRL\/878\/03 - Final June 2003 EMEA London. Available in:https:\/\/www.ema.europa.eu\/en\/documents\/mrl\u2010report\/metamizole\u2010summary\u2010report\u20102\u2010committee\u2010veterinary\u2010medicinal\u2010products_en.pdf"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12342"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smallrumres.2015.10.005"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12484"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042\u20103292.2011.00291.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06\u20108061com"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467\u20102995.2011.00617.x"},{"key":"e_1_2_9_18_1","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use(2016).Harmonized Tripartite Guideline for Good Clinical Practice ICH E6(R2) Integrated Addedum. Geneva"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2478\/pjvs\u20102014\u20100030"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12679"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12471"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010199528030\u201000004"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510150102"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cveq.2019.08.007"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119404576.ch5"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.80.3.294"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12935"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/evj.13306"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2011.11.028"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000720"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917\u2010015\u20100395\u20108"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00314805"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2015.05.004"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00547371"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.12998","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvp.12998","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.12998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T15:17:15Z","timestamp":1692803835000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvp.12998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1111\/jvp.12998"],"URL":"https:\/\/doi.org\/10.1111\/jvp.12998","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,15]]},"assertion":[{"value":"2021-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}